These results provide the biological and molecular rationales for the dual-targeting strategy for RSK2 and AKT, which may overcome the therapeutic difficulty due to cytogenetic/molecular heterogeneity in MM. This evidence concerns the gene RPS6KA3 and Miyoshi myopathy.